New perspectives on osteogenesis imperfecta

Nature Reviews Endocrinology

Volumn 7, Issue 9, 2011, Pages 540-557

  Forlino, Antonella ^a,b   Cabral, Wayne A ^b   Barnes, Aileen M ^b   Marini, Joan C ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CHAPERONE; COLLAGEN TYPE 1; COLLAGEN TYPE 3; DENOSUMAB; HUMAN GROWTH HORMONE; PEPTIDYLPROLYL ISOMERASE;

AORTA ANOMALY; AORTA VALVE DISEASE; AUTOSOMAL DOMINANT DISORDER; AUTOSOMAL RECESSIVE DISORDER; BONE DENSITOMETRY; BONE MINERALIZATION; BRACE; CELL INTERACTION; CELL STRESS; CLINICAL TRIAL (TOPIC); COR PULMONALE; DISEASE CLASSIFICATION; GENE MUTATION; GENE SILENCING; HEARING LOSS; HEART ATRIUM SEPTUM DEFECT; HUMAN; HYDROCEPHALUS; HYDROXYLATION; INTRAMEDULLARY NAILING; MACROCEPHALY; MESENCHYMAL STEM CELL TRANSPLANTATION; MORBIDITY; MORPHOMETRICS; MORTALITY; NONHUMAN; NONSENSE MEDIATED MRNA DECAY; OSTEOGENESIS IMPERFECTA; PHENOTYPE; PHYSIOTHERAPY; PNEUMONIA; PRIORITY JOURNAL; PROTEIN DEFECT; REVIEW; SCOLIOSIS; SHORT STATURE; SYRINGOMYELIA; THORAX DEFORMITY; TOOTH MALFORMATION; TOOTH PULP DISEASE;

ANIMALS; COLLAGEN TYPE I; HUMANS; OSTEOGENESIS IMPERFECTA; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 80052053073     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2011.81     Document Type: Review

References (215)

1. Marini, J. C. in Nelson Textbook of Pediatrics (eds Behrman, R. E., Kliegman, R. M. & Jensen, R. M.) 2336-2338 (Saunders, Philadelphia, 2004).
2. Marini, J. C. et al. Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. Hum. Mutat. 28, 209-221 (2007).
3. Prockop, D. J. & Kivirikko, K. I. Collagens: molecular biology, diseases, and potentials for therapy. Annu. Rev. Biochem. 64, 403-434 (1995).
4. Myllyharju, J. & Kivirikko, K. I. Collagens, modifying enzymes and their mutations in humans, flies and worms. Trends Genet. 20, 33-43 (2004). (Pubitemid 38032818)
5. Morello, R. et al. CRTAP is required for prolyl 3- hydroxylation and mutations cause recessive osteogenesis imperfecta. Cell 127, 291-304 (2006). (Pubitemid 44604299)
6. Barnes, A. M. et al. Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta. N. Engl. J. Med. 355, 2757-2764 (2006). (Pubitemid 46021513)
7. Cabral, W. A. et al. Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta. Nat. Genet. 39, 359-365 (2007). (Pubitemid 46328489)
8. Barnes, A. M. et al. Lack of cyclophilin B in osteogenesis imperfecta with normal collagen folding. N. Engl. J. Med. 362, 521-528 (2010).
9. van Dijk, F. S. et al. PPIB mutations cause severe osteogenesis imperfecta. Am. J. Hum. Genet. 85, 521-527 (2009).
10. Baldridge, D. et al. CRTAP and LEPRE1 mutations in recessive osteogenesis imperfecta. Hum. Mutat. 29, 1435-1442 (2008). (Pubitemid 352774897)
11. Alanay, Y. et al. Mutations in the gene encoding the RER protein FKBP65 cause autosomal-recessive osteogenesis imperfecta. Am. J. Hum. Genet. 86, 551-559 (2010).
12. Christiansen, H. E. et al. Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results in severe recessive osteogenesis imperfecta. Am. J. Hum. Genet. 86, 389-398 (2010).
13. Sillence, D. O. & Rimoin, D. L. Classification of osteogenesis imperfecta. Lancet 1, 1041-1042 (1978).
14. Sillence, D. O., Senn, A. & Danks, D. M. Genetic heterogeneity in osteogenesis imperfecta. J. Med. Genet. 16, 101-116 (1979). (Pubitemid 9164903)
15. Bishop, N. Characterising and treating osteogenesis imperfecta. Early Hum. Dev. 86, 743-746 (2010).
16. Van Dijk, F. S., Pals, G., Van Rijn, R. R., Nikkels, P. G. & Cobben, J. M. Classification of Osteogenesis Imperfecta revisited. Eur. J. Med. Genet. 53, 1-5 (2010).
17. Glorieux, F. H. Osteogenesis imperfecta. Best. Pract. Res. Clin. Rheumatol. 22, 85-100 (2008). (Pubitemid 351325741)
18. McAllion, S. J. & Paterson, C. R. Causes of death in osteogenesis imperfecta. J. Clin. Pathol. 49, 627-630 (1996). (Pubitemid 26264386)
19. Thibeault, D. W., Pettett, G., Mabry, S. M. & Rezaiekhaligh, M. M. Osteogenesis imperfecta Type IIA and pulmonary hypoplasia with normal alveolar development. Pediatr. Pulmonol. 20, 301-306 (1995).
20. Obafemi, A. A., Bulas, D. I., Troendle, J. & Marini, J. C. Popcorn calcification in osteogenesis imperfecta: incidence, progression, and molecular correlation. Am. J. Med. Genet. A 146A, 2725-2732 (2008).
21. Rauch, F. & Glorieux, F. H. Osteogenesis imperfecta. Lancet 363, 1377-1385 (2004). (Pubitemid 38529880)
22. Rauch, F., Travers, R., Parfitt, A. M. & Glorieux, F. H. Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone 26, 581-589 (2000). (Pubitemid 30301650)
23. Lund, A. M., Mølgaard, C., Müller, J. & Skovby, F. Bone mineral content and collagen defects in osteogenesis imperfecta. Acta Paediatr. 88, 1083-1088 (1999). (Pubitemid 29489164)
24. Rauch, F., Lalic, L., Roughley, P. & Glorieux, F. H. Relationship between genotype and skeletal phenotype in children and adolescents with osteogenesis imperfecta. J. Bone Miner. Res. 25, 1367-1374 (2010).
25. Chavassieux, P., Seeman, E. & Delmas, P. D. Insights into material and structural basis of bone fragility from diseases associated with fractures: how determinants of the biomechanical properties of bone are compromised by disease. Endocr. Rev. 28, 151-164 (2007). (Pubitemid 46984832)
26. Uveges, T. E. et al. Cellular mechanism of decreased bone in Brtl mouse model of OI: imbalance of decreased osteoblast function and increased osteoclasts and their precursors. J. Bone Miner. Res. 23, 1983-1994 (2008).
27. Li, H. et al. Immature osteoblast lineage cells increase osteoclastogenesis in osteogenesis imperfecta murine. Am. J. Pathol. 176, 2405-2413 (2010).
28. Forlino, A. et al. Differential expression of both extracellular and intracellular proteins is involved in the lethal or nonlethal phenotypic variation of BrtlIV, a murine model for osteogenesis imperfecta. Proteomics 7, 1877-1891 (2007). (Pubitemid 46911006)
29. Daley, E. et al. Variable bone fragility associated with an Amish COL1A2 variant and a knock-in mouse model. J. Bone Miner. Res. 25, 247-261 (2010).
30. Carleton, S. M. et al. Role of genetic background in determining phenotypic severity throughout postnatal development and at peak bone mass in Col1a2 deficient mice (oim). Bone 42, 681-694 (2008).
31. Forlino, A., Kuznetsova, N. V., Marini, J. C. & Leikin, S. Selective retention and degradation of molecules with a single mutant alpha1(I) chain in the Brtl IV mouse model of OI. Matrix Biol. 26, 604-614 (2007). (Pubitemid 350180392)
32. Lisse, T. S. et al. ER stress-mediated apoptosis in a new mouse model of osteogenesis imperfecta. PLoS Genet. 4, e7 (2008).
33. Mehrotra, M., Rosol, M., Ogawa, M. & Larue, A. C. Amelioration of a mouse model of osteogenesis imperfecta with hematopoietic stem cell transplantation: microcomputed tomography studies. Exp. Hematol. 38, 593-602 (2010).
34. Panaroni, C. et al. In utero transplantation of adult bone marrow decreases perinatal lethality and rescues the bone phenotype in the knockin murine model for classical, dominant osteogenesis imperfecta. Blood 114, 459-468 (2009).
35. Wang, X., Li, F. & Niyibizi, C. Progenitors systemically transplanted into neonatal mice localize to areas of active bone formation in vivo: implications of cell therapy for skeletal diseases. Stem Cells 24, 1869-1878 (2006). (Pubitemid 44474163)
36. Canty, E. G. & Kadler, K. E. Procollagen trafficking, processing and fibrillogenesis. J. Cell Sci. 118, 1341-1353 (2005). (Pubitemid 40585115)
37. Schnieke, A., Harbers, K. & Jaenisch, R. Embryonic lethal mutation in mice induced by retrovirus insertion into the alpha 1(I) collagen gene. Nature 304, 315-320 (1983). (Pubitemid 13072750)
38. Malfait, F. et al. Total absence of the alpha2(I) chain of collagen type I causes a rare form of Ehlers-Danlos syndrome with hypermobility and propensity to cardiac valvular problems. J. Med. Genet. 43, e36 (2006).
39. Nicholls, A. C. et al. The clinical features of homozygous alpha 2(I) collagen deficient osteogenesis imperfecta. J. Med. Genet. 21, 257-262 (1984). (Pubitemid 14094462)
40. Raghunath, M., Bruckner, P. & Steinmann, B. Delayed triple helix formation of mutant collagen from patients with osteogenesis imperfecta. J. Mol. Biol. 236, 940-949 (1994). (Pubitemid 24146332)
41. Bodian, D. L. et al. Mutation and polymorphism spectrum in osteogenesis imperfecta type II: implications for genotype-phenotype relationships. Hum. Mol. Genet. 18, 463-471 (2009).
42. Di Lullo, G. A., Sweeney, S. M., Korkko, J., Ala-Kokko, L. & San Antonio, J. D. Mapping the ligand-binding sites and disease-associated mutations on the most abundant protein in the human, type I collagen. J. Biol. Chem. 277, 4223-4231 (2002). (Pubitemid 34968685)
43. Sweeney, S. M. et al. Candidate cell and matrix interaction domains on the collagen fibril, the predominant protein of vertebrates. J. Biol. Chem. 283, 21187-21197 (2008).
44. Cabral, W. A. et al. Mutations near amino end of alpha(I) collagen cause combined osteogenesis imperfecta/Ehlers-Danlos syndrome by interference with N-propeptide processing. J. Biol. Chem. 280, 19259-19269 (2005). (Pubitemid 41379633)
45. Makareeva, E., Cabral, W. A., Marini, J. C. & Leikin, S. Molecular mechanism of alpha 1(I)-osteogenesis imperfecta/Ehlers-Danlos syndrome: unfolding of an N-anchor domain at the N-terminal end of the type I collagen triple helix. J. Biol. Chem. 281, 6463-6470 (2006). (Pubitemid 43847579)
46. Dombrowski, K. E., Vogel, B. E. & Prockop, D. J. Mutations that alter the primary structure of type I procollagen have long-range effects on its cleavage by procollagen N-proteinase. Biochemistry 28, 7107-7112 (1989). (Pubitemid 19219900)
47. Sippola, M., Kaffe, S. & Prockop, D. J. A heterozygous defect for structurally altered pro-alpha 2 chain of type I procollagen in a mild variant of osteogenesis imperfecta. The altered structure decreases the thermal stability of procollagen and makes it resistant to procollagen N-proteinase. J. Biol. Chem. 259, 14094-14100 (1984). (Pubitemid 15223981)
48. Feshchenko, S. et al. Identification of a new heterozygous point mutation in the COL1A2 gene leading to skipping of exon 9 in a patient with joint laxity, hyperextensibility of skin and blue sclerae. Mutations in brief no. 166. Online. Hum. Mutat. 12, 138 (1998).
49. Nicholls, A. C., Oliver, J., Renouf, D. V., Heath, D. A. & Pope, F. M. The molecular defect in a family with mild atypical osteogenesis imperfecta and extreme joint hypermobility: exon skipping caused by an 11-bp deletion from an intron in one COL1A2 allele. Hum. Genet. 88, 627-633 (1992).
50. Raff, M. L., Craigen, W. J., Smith, L. T., Keene, D. R. & Byers, P. H. Partial COL1A2 gene duplication produces features of osteogenesis imperfecta and Ehlers-Danlos syndrome type VII. Hum. Genet. 106, 19-28 (2000). (Pubitemid 30156389)
51. Lindahl, K. et al. COL1 C-propeptide cleavage site mutations cause high bone mass osteogenesis imperfecta. Hum. Mutat. doi:10.1002/humu.21475.
52. Cole, W. G., Campbell, P. E., Rogers, J. G. & Bateman, J. F. The clinical features of osteogenesis imperfecta resulting from a non-functional carboxy terminal pro alpha 1(I) propeptide of type I procollagen and a severe deficiency of normal type I collagen in tissues. J. Med. Genet. 27, 545-551 (1990).
53. Chessler, S. D., Wallis, G. A. & Byers, P. H. Mutations in the carboxyl-terminal propeptide of the pro alpha 1(I) chain of type I collagen result in defective chain association and produce lethal osteogenesis imperfecta. J. Biol. Chem. 268, 18218-18225 (1993). (Pubitemid 23260346)
54. Pace, J. M. et al. Defective C-propeptides of the proalpha2(I) chain of type I procollagen impede molecular assembly and result in osteogenesis imperfecta. J. Biol. Chem. 283, 16061-16067 (2008).
55. Willing, M. C., Cohn, D. H. & Byers, P. H. Frameshift mutation near the 3′ end of the COL1A1 gene of type I collagen predicts an elongated Pro alpha 1(I) chain and results in osteogenesis imperfecta type I. J. Clin. Invest. 85, 282-290 (1990). (Pubitemid 20030320)
56. Pace, J. M., Atkinson, M., Willing, M. C., Wallis, G. & Byers, P. H. Deletions and duplications of Gly-Xaa-Yaa triplet repeats in the triple helical domains of type I collagen chains disrupt helix formation and result in several types of osteogenesis imperfecta. Hum. Mutat. 18, 319-326 (2001). (Pubitemid 32916862)
57. Cabral, W. A. et al. Type I collagen triplet duplication mutation in lethal osteogenesis imperfecta shifts register of alpha chains throughout the helix and disrupts incorporation of mutant helices into fibrils and extracellular matrix. J. Biol. Chem. 278, 10006-10012 (2003). (Pubitemid 36800253)
58. Cabral, W. A. et al. γ-position cysteine substitution in type I collagen (alpha1(I) R888C/p.R1066C) is associated with osteogenesis imperfecta/Ehlers-Danlos syndrome phenotype. Hum. Mutat. 28, 396-405 (2007). (Pubitemid 46542926)
59. Malfait, F. et al. Three arginine to cysteine substitutions in the pro-alpha (I)-collagen chain cause Ehlers-Danlos syndrome with a propensity to arterial rupture in early adulthood. Hum. Mutat. 28, 387-395 (2007). (Pubitemid 46542925)
60. Gensure, R. C. et al. A novel COL1A1 mutation in infantile cortical hyperostosis (Caffey disease) expands the spectrum of collagen-related disorders. J. Clin. Invest. 115, 1250-1257 (2005). (Pubitemid 40629043)
61. Suphapeetiporn, K., Tongkobpetch, S., Mahayosnond, A. & Shotelersuk, V. Expanding the phenotypic spectrum of Caffey disease. Clin. Genet. 71, 280-284 (2007). (Pubitemid 46322668)
62. Cho, T. J. et al. The c.3040C ≥ T mutation in COL1A1 is recurrent in Korean patients with infantile cortical hyperostosis (Caffey disease). J. Hum. Genet. 53, 947-949 (2008).
63. Boot-Handford, R. P. & Briggs, M. D. The unfolded protein response and its relevance to connective tissue diseases. Cell Tissue Res. 339, 197-211 (2009).
64. Ishida, Y. et al. Autophagic elimination of misfolded procollagen aggregates in the endoplasmic reticulum as a means of cell protection. Mol. Biol. Cell 20, 2744-2754 (2009).
65. Lamandé, S. R. et al. Endoplasmic reticulum-mediated quality control of type I collagen production by cells from osteogenesis imperfecta patients with mutations in the pro alpha 1 (I) chain carboxyl-terminal propeptide which impair subunit assembly. J. Biol. Chem. 270, 8642-8649 (1995).
66. Fitzgerald, J., Lamandé, S. R. & Bateman, J. F. Proteasomal degradation of unassembled mutant type I collagen pro-alpha1(I) chains. J. Biol. Chem. 274, 27392-27398 (1999).
67. Forlino, A. et al. in 9th International Meeting on Osteogenesis Imperfecta (Annapolis, MD, USA, 2005).
68. Fedarko, N. S., Robey, P. G. & Vetter, U. K. Extracellular matrix stoichiometry in osteoblasts from patients with osteogenesis imperfecta. J. Bone Miner. Res. 10, 1122-1129 (1995).
69. Fedarko, N. S., Sponseller, P. D. & Shapiro, J. R. Long-term extracellular matrix metabolism by cultured human osteogenesis imperfecta osteoblasts. J. Bone Miner. Res. 11, 800-805 (1996). (Pubitemid 26172804)
70. Wallace, J. M., Orr, B. G., Marini, J. C. & Holl, M. M. Nanoscale morphology of Type I collagen is altered in the Brtl mouse model of osteogenesis imperfecta. J. Struct. Biol. 173, 146-152 (2011).
71. Fratzl-Zelman, N. et al. CRTAP deficiency leads to abnormally high bone matrix mineralization in a murine model and in children with osteogenesis imperfecta type VII. Bone 46, 820-826 (2009).
72. Roschger, P. et al. Evidence that abnormal high bone mineralization in growing children with osteogenesis imperfecta is not associated with specific collagen mutations. Calcif. Tissue Int. 82, 263-270 (2008).
73. Vetter, U. et al. Osteogenesis imperfecta: changes in noncollagenous proteins in bone. J. Bone Miner. Res. 6, 501-505 (1991).
74. Ganss, B., Kim, R. H. & Sodek, J. Bone sialoprotein. Crit. Rev. Oral Biol. Med. 10, 79-98 (1999). (Pubitemid 29510048)
75. Camacho, N. P., Landis, W. J. & Boskey, A. L. Mineral changes in a mouse model of osteogenesis imperfecta detected by Fourier transform infrared microscopy. Connect. Tissue Res. 35, 259-265 (1996). (Pubitemid 27118857)
76. Renders, G. A., Mulder, L., Langenbach, G. E., van Ruijven, L. J. & van Eijden, T. M. Biomechanical effect of mineral heterogeneity in trabecular bone. J. Biomech. 41, 2793-2798 (2008).
77. Gourion-Arsiquaud, S. et al. Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity. Bone 46, 666-672 (2010).
78. Nakahama, K. I. Cellular communications in bone homeostasis and repair. Cell. Mol. Life Sci. 67, 4001-4009 (2010).
79. Poole, K. E. et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 19, 1842-1844 (2005). (Pubitemid 41598769)
80. Sarathchandra, P., Pope, F. M., Kayser, M. V. & Ali, S. Y. A light and electron microscopic study of osteogenesis imperfecta bone samples, with reference to collagen chemistry and clinical phenotype. J. Pathol. 192, 385-395 (2000).
81. Fernandes, H. et al. The role of collagen crosslinking in differentiation of human mesenchymal stem cells and MC3T3-E1 cells. Tissue Eng. Part A 15, 3857-3867 (2009).
82. Bank, R. A. et al. Pyridinium cross-links in bone of patients with osteogenesis imperfecta: evidence of a normal intrafibrillar collagen packing. J. Bone Miner. Res. 15, 1330-1336 (2000). (Pubitemid 30413865)
83. Vranka, J. A., Sakai, L. Y. & Bächinger, H. P. Prolyl 3-hydroxylase 1, enzyme characterization and identification of a novel family of enzymes. J. Biol. Chem. 279, 23615-23621 (2004). (Pubitemid 38685676)
84. Weis, M. A. et al. Location of 3-hydroxyproline residues in collagen types, I, II, III, and V/XI implies a role in fibril supramolecular assembly. J. Biol. Chem. 285, 2580-2590 (2009).
85. Ishikawa, Y., Wirz, J., Vranka, J. A., Nagata, K. & Bächinger, H. P. Biochemical characterization of the prolyl 3-hydroxylase 1.cartilage-associated protein.cyclophilin B complex. J. Biol. Chem. 284, 17641-17647 (2009).
86. Castagnola, P. et al. Cartilage associated protein (CASP) is a novel developmentally regulated chick embryo protein. J. Cell Sci. 110 (Pt 12), 1351-1359 (1997). (Pubitemid 27299931)
87. Wassenhove-McCarthy, D. J. & McCarthy, K. J. Molecular characterization of a novel basement membrane-associated proteoglycan, leprecan. J. Biol. Chem. 274, 25004-25017 (1999).
88. Labuda, M. et al. Osteogenesis imperfecta type VII maps to the short arm of chromosome 3. Bone 31, 19-25 (2002). (Pubitemid 34754420)
89. Marini, J. C., Cabral, W. A., Barnes, A. M. & Chang, W. Components of the collagen prolyl 3-hydroxylation complex are crucial for normal bone development. Cell Cycle 6, 1675-1681 (2007). (Pubitemid 47327916)
90. Morello, R. et al. cDNA cloning, characterization and chromosome mapping of Crtap encoding the mouse cartilage associated protein. Matrix Biol. 18, 319-324 (1999). (Pubitemid 29324746)
91. Marini, J. C., Cabral, W. A. & Barnes, A. M. Null mutations in LEPRE1 and CRTAP cause severe recessive osteogenesis imperfecta. Cell Tissue Res. 339, 59-70 (2009).
92. Baldridge, D. et al. Generalized connective tissue disease in Crtap-/- mouse. PLoS ONE 5, e10560 (2010).
93. Willaert, A. et al. Recessive osteogenesis imperfecta caused by LEPRE1 mutations: clinical documentation and identification of the splice form responsible for prolyl 3-hydroxylation. J. Med. Genet. 46, 233-241 (2009).
94. Vranka, J., Stadler, H. S. & Bächinger, H. P. Expression of prolyl 3-hydroxylase genes in embryonic and adult mouse tissues. Cell Struct. Funct. 34, 97-104 (2009).
95. Cabral, W. A. et al. A founder mutation in LEPRE1 causes lethal recessive type VIII osteogenesis imperfecta and occurs in West Africans and African Americans. Presented at the European Society of Human Genetics Annual Conference (Gothenburg, Sweden, 2010).
96. Vranka, J. A. et al. Prolyl 3-hydroxylase 1 null mice display abnormalities in fibrillar collagen-rich tissues such as tendons, skin, and bones. J. Biol. Chem. 285, 17253-17262 (2010).
97. Bächinger, H. P. The influence of peptidyl-prolyl cis-trans isomerase on the in vitro folding of type III collagen. J. Biol. Chem. 262, 17144-17148 (1987).
98. Steinmann, B., Bruckner, P. & Superti-Furga, A. Cyclosporin A slows collagen triple-helix formation in vivo: indirect evidence for a physiologic role of peptidyl-prolyl cis-trans-isomerase. J. Biol. Chem. 266, 1299-1303 (1991). (Pubitemid 21907258)
99. Pyott, S. M. et al. Mutations in PPIB (cyclophilin B) delay type I procollagen chain association and result in perinatal lethal to moderate osteogenesis imperfecta phenotypes. Hum. Mol. Genet. 20, 1595-1609 (2011).
100. Van Dijk, F. S., Cobben, J. M. & Pals, G. Osteogenesis imperfecta, normal collagen folding, and lack of cyclophilin B. N. Engl. J. Med. 362, 1940-1941 (2010).
101. Choi, J. W. et al. Severe osteogenesis imperfecta in cyclophilin B-deficient mice. PLoS Genet. 5, e1000750 (2009).
102. Chang, W., Barnes, A. M., Cabral, W. A., Bodurtha, J. N. & Marini, J. C. Prolyl 3-hydroxylase 1 and CRTAP are mutually stabilizing in the endoplasmic reticulum collagen prolyl 3-hydroxylation complex. Hum. Mol. Genet. 19, 223-234 (2009).
103. Mizuno, K., Peyton, D. H., Hayashi, T., Engel, J. & Bächinger, H. P. Effect of the -Gly-3(S.)-hydroxyprolyl-4(R.)-hydroxyprolyl-tripeptide unit on the stability of collagen model peptides. FEBS J. 275, 5830-5840 (2008).
104. Glorieux, F. H. et al. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J. Bone Miner. Res. 17, 30-38 (2002). (Pubitemid 33150994)
105. Becker, J. et al. Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta. Am. J. Hum. Genet. 88, 362-371 (2011).
106. Doll, J. A. et al. Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas. Nat. Med. 9, 774-780 (2003). (Pubitemid 36749229)
107. Smith, T., Ferreira, L. R., Hebert, C., Norris, K. & Sauk, J. J. Hsp47 and cyclophilin B traverse the endoplasmic reticulum with procollagen into pre-Golgi intermediate vesicles. A role for Hsp47 and cyclophilin B in the export of procollagen from the endoplasmic reticulum. J. Biol. Chem. 270, 18323-18328 (1995).
108. Nagai, N. et al. Embryonic lethality of molecular chaperone hsp47 knockout mice is associated with defects in collagen biosynthesis. J. Cell Biol. 150, 1499-1506 (2000).
109. Ishida, Y. et al. Type I collagen in Hsp47-null cells is aggregated in endoplasmic reticulum and deficient in N-propeptide processing and fibrillogenesis. Mol. Biol. Cell 17, 2346-2355 (2006). (Pubitemid 44011749)
110. Ishida, Y. & Nagata, K. Autophagy eliminates a specific species of misfolded procollagen and plays a protective role in cell survival against ER stress. Autophagy 5, 1217-1219 (2009).
111. Drögemüller, C. et al. A missense mutation in the SERPINH1 gene in Dachshunds with osteogenesis imperfecta. PLoS Genet. 5, e1000579 (2009).
112. Ishikawa, Y., Vranka, J., Wirz, J., Nagata, K. & Bächinger, H. P. The rough endoplasmic reticulum-resident FK506-binding protein FKBP65 is a molecular chaperone that interacts with collagens. J. Biol. Chem. 283, 31584-31590 (2008).
113. Breslau-Siderius, E. J., Engelbert, R. H., Pals, G. & van der Sluijs, J. A. Bruck syndrome: a rare combination of bone fragility and multiple congenital joint contractures. J. Pediatr. Orthop. B. 7, 35-38 (1998). (Pubitemid 28076752)
114. Shaheen, R., Al-Owain, M., Sakati, N., Alzayed, Z. S. & Alkuraya, F. S. FKBP10 and bruck syndrome: Phenotypic heterogeneity or call for reclassification? Am. J. Hum. Genet. 87, 571 (2010).
115. Kelley, B. P. et al. Mutations in FKBP10 cause recessive osteogenesis imperfecta and type 1 Bruck syndrome. J. Bone Miner. Res. 26, 666-672 (2010).
116. Bank, R. A. et al. Defective collagen crosslinking in bone, but not in ligament or cartilage, in Bruck syndrome: indications for a bone-specific telopeptide lysyl hydroxylase on chromosome 17. Proc. Natl Acad. Sci. USA 96, 1054-1058 (1999). (Pubitemid 29072182)
117. van der Slot, A. J. et al. Identification of PLOD2 as telopeptide lysyl hydroxylase, an important enzyme in fibrosis. J. Biol. Chem. 278, 40967-40972 (2003).
118. Szpirer, C. et al. Localization of the gene encoding a novel isoform of lysyl hydroxylase. Mamm. Genome 8, 707-708 (1997). (Pubitemid 28060634)
119. Lapunzina, P. et al. Identification of a frameshift mutation in Osterix in a patient with recessive osteogenesis imperfecta. Am. J. Hum. Genet. 87, 110-114 (2010).
120. Suske, G., Bruford, E. & Philipsen, S. Mammalian SP/KLF transcription factors: bring in the family. Genomics 85, 551-556 (2005). (Pubitemid 40463690)
121. Nakashima, K. et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108, 17-29 (2002). (Pubitemid 34137009)
122. Pedersen, U. Hearing loss in patients with osteogenesis imperfecta. A clinical and audiological study of 201 patients. Scand. Audiol. 13, 67-74 (1984). (Pubitemid 14123814)
123. Kuurila, K., Grénman, R., Johansson, R. & Kaitila, I. Hearing loss in children with osteogenesis imperfecta. Eur. J. Pediatr. 159, 515-519 (2000). (Pubitemid 30418996)
124. Paterson, C. R., Monk, E. A. & McAllion, S. J. How common is hearing impairment in osteogenesis imperfecta? J. Laryngol. Otol. 115, 280-282 (2001). (Pubitemid 32324594)
125. Kuurila, K., Kaitila, I., Johansson, R. & Grénman, R. Hearing loss in Finnish adults with osteogenesis imperfecta: a nationwide survey. Ann. Otol. Rhinol. Laryngol. 111, 939-946 (2002). (Pubitemid 35155071)
126. Hartikka, H. et al. Lack of correlation between the type of COL1A1 or COL1A2 mutation and hearing loss in osteogenesis imperfecta patients. Hum. Mutat. 24, 147-154 (2004). (Pubitemid 39006594)
127. Kuurila, K. et al. Vestibular dysfunction in adult patients with osteogenesis imperfecta. Am. J. Med. Genet. A. 120A, 350-358 (2003). (Pubitemid 37063769)
128. Pedersen, U. & Elbrønd, O. Stapedectomy in osteogenesis imperfecta. ORL J. Otorhinolaryngol Relat. Spec. 45, 330-337 (1983). (Pubitemid 14243043)
129. Garretsen, A. J., Cremers, C. W. & Huygén, P. L. Hearing loss (in nonoperated ears) in relation to age in osteogenesis imperfecta type, I. Ann. Otol. Rhinol. Laryngol. 106, 575-582 (1997).
130. Shea, J. J. & Postma, D. S. Findings and long-term surgical results in the hearing loss of osteogenesis imperfecta. Arch. Otolaryngol. 108, 467-470 (1982). (Pubitemid 12050357)
131. van der Rijt, A. J. & Cremers, C. W. Stapes surgery in osteogenesis imperfecta: results of a new series. Otol. Neurootol. 24, 717-722 (2003). (Pubitemid 37122534)
132. Kuurila, K., Pynnönen, S. & Grénman, R. Stapes surgery in osteogenesis imperfecta in Finland. Ann. Otol. Rhinol. Laryngol. 113, 187-193 (2004). (Pubitemid 38337761)
133. Rotteveel, L. J. et al. Cochlear implantation in 3 patients with osteogenesis imperfecta: imaging, surgery and programming issues. Audiol. Neurootol. 13, 73-85 (2008). (Pubitemid 351225886)
134. Levin, L. S., Salinas, C. F. & Jorgenson, R. J. Classification of osteogenesis imperfecta by dental characteristics. Lancet 1, 332-333 (1978). (Pubitemid 8273583)
135. OConnell, A. C. & Marini, J. C. Evaluation of oral problems in an osteogenesis imperfecta population. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 87, 189-196 (1999).
136. Malmgren, B. & Norgren, S. Dental aberrations in children and adolescents with osteogenesis imperfecta. Acta Odontol. Scand. 60, 65-71 (2002).
137. Majorana, A. et al. Dentinogenesis imperfecta in children with osteogenesis imperfecta: a clinical and ultrastructural study. Int. J. Paediatr. Dent. 20, 112-118 (2010).
138. Waltimo, J., Ojanotko-Harri, A. & Lukinmaa, P. L. Mild forms of dentinogenesis imperfecta in association with osteogenesis imperfecta as characterized by light and transmission electron microscopy. J. Oral Pathol. Med. 25, 256-264 (1996). (Pubitemid 126447420)
139. Lund, A. M., Jensen, B. L., Nielsen, L. A. & Skovby, F. Dental manifestations of osteogenesis imperfecta and abnormalities of collagen I metabolism. J. Craniofac. Genet. Dev. Biol. 18, 30-37 (1998). (Pubitemid 28181863)
140. Rauch, F., Lalic, L., Roughley, P. & Glorieux, F. H. Genotype-phenotype correlations in nonlethal osteogenesis imperfecta caused by mutations in the helical domain of collagen type I. Eur. J. Hum. Genet. 18, 642-647 (2010).
141. Schwarz, M., Harbers, K. & Kratochwil, K. Transcription of a mutant collagen I gene is a cell type and stage-specific marker for odontoblast and osteoblast differentiation. Development 108, 717-726 (1990).
142. Waltimo, J. Hyperfibers and vesicles in dentin matrix in dentinogenesis imperfecta (DI) associated with osteogenesis imperfecta (OI). J. Oral Pathol. Med. 23, 389-393 (1994).
143. Lygidakis, N. A., Smith, R. & Oulis, C. J. Scanning electron microscopy of teeth in osteogenesis imperfecta type I. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 81, 567-572 (1996). (Pubitemid 126808129)
144. Hall, R. K., Manière, M. C., Palamara, J. & Hemmerle, J. Odontoblast dysfunction in osteogenesis imperfecta: an, LM, SEM, and ultrastructural study. Connect. Tissue Res. 43, 401-405 (2002). (Pubitemid 34777955)
145. Charnas, L. R. & Marini, J. C. Communicating hydrocephalus, basilar invagination, and other neurologic features in osteogenesis imperfecta. Neurology 43, 2603-2608 (1993). (Pubitemid 24004553)
146. Sawin, P. D. & Menezes, A. H. Basilar invagination in osteogenesis imperfecta and related osteochondrodysplasias: medical and surgical management. J. Neurosurg. 86, 950-960 (1997). (Pubitemid 27230137)
147. Menezes, A. H. Specific entities affecting the craniocervical region: osteogenesis imperfecta and related osteochondrodysplasias: medical and surgical management of basilar impression. Childs Nerv. Syst. 24, 1169-1172 (2008).
148. Marini, J. C., Bordenick, S., Heavner, G., Rose, S. & Chrousos, G. P. Evaluation of growth hormone axis and responsiveness to growth stimulation of short children with osteogenesis imperfecta. Am. J. Med. Genet. 45, 261-264 (1993). (Pubitemid 23030706)
149. Marini, J. C. et al. Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: high predictive value of the carboxyterminal propeptide of type I procollagen. J. Bone Miner. Res. 18, 237-243 (2003). (Pubitemid 36125916)
150. Singer, R. B., Ogston, S. A. & Paterson, C. R. Mortality in various types of osteogenesis imperfecta. J. Insur. Med. 33, 216-220 (2001).
151. Widmann, R. F. et al. Spinal deformity, pulmonary compromise, and quality of life in osteogenesis imperfecta. Spine (Phila. Pa 1976) 24, 1673-1678 (1999). (Pubitemid 29387923)
152. Shapiro, J. R. et al. Pulmonary hypoplasia and osteogenesis imperfecta type II with defective synthesis of alpha I(1) procollagen. Bone 10, 165-171 (1989). (Pubitemid 19249342)
153. Hortop, J., Tsipouras, P., Hanley, J. A., Maron, B. J. & Shapiro, J. R. Cardiovascular involvement in osteogenesis imperfecta. Circulation 73, 54-61 (1986). (Pubitemid 16132412)
154. Bonita, R. E., Cohen, I. S. & Berko, B. A. Valvular heart disease in osteogenesis imperfecta: presentation of a case and review of the literature. Echocardiography 27, 69-73 (2010).
155. Migliaccio, S. et al. Impairment of diastolic function in adult patients affected by osteogenesis imperfecta clinically asymptomatic for cardiac disease: casuality or causality? Int. J. Cardiol. 131, 200-203 (2009).
156. Huang, R. P., Ambrose, C. G., Sullivan, E. & Haynes, R. J. Functional significance of bone density measurements in children with osteogenesis imperfecta. J. Bone Joint Surg. Am. 88, 1324-1330 (2006). (Pubitemid 43837128)
157. Letocha, A. D. et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J. Bone Miner. Res. 20, 977-986 (2005). (Pubitemid 40712822)
158. Sakkers, R. et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet 363, 1427-1431 (2004). (Pubitemid 38586718)
159. Engelbert, R. H. et al. Scoliosis in children with osteogenesis imperfecta: influence of severity of disease and age of reaching motor milestones. Eur. Spine J. 12, 130-134 (2003). (Pubitemid 36566766)
160. Cintas, H. L., Siegel, K. L., Furst, G. P. & Gerber, L. H. Brief assessment of motor function: reliability and concurrent validity of the Gross Motor Scale. Am. J. Phys. Med. Rehabil. 82, 33-41 (2003). (Pubitemid 36043761)
161. Ruck-Gibis, J., Plotkin, H., Hanley, J. & Wood-Dauphinee, S. Reliability of the gross motor function measure for children with osteogenesis imperfecta. Pediatr. Phys. Ther. 13, 10-17 (2001). (Pubitemid 32223494)
162. Bleck, E. E. Nonoperative treatment of osteogenesis imperfecta: orthotic and mobility management. Clin. Orthop. Relat. Res. 111-122 (1981). (Pubitemid 11000297)
163. Engelbert, R. H. et al. Osteogenesis imperfecta in childhood: impairment and disability. A prospective study with 4-year follow-up. Arch. Phys. Med. Rehabil. 85, 772-778 (2004). (Pubitemid 38857914)
164. Takken, T. et al. Cardiopulmonary fitness and muscle strength in patients with osteogenesis imperfecta type I. J. Pediatr. 145, 813-818 (2004). (Pubitemid 39591633)
165. Van Brussel, M. et al. Physical training in children with osteogenesis imperfecta. J. Pediatr. 152, 111-116 (2008).
166. Semler, O., Fricke, O., Vezyroglou, K., Stark, C. & Schoenau, E. Preliminary results on the mobility after whole body vibration in immobilized children and adolescents. J. Musculoskelet. Neuronal Interact. 7, 77-81 (2007). (Pubitemid 46730309)
167. Luhmann, S. J., Sheridan, J. J., Capelli, A. M. & Schoenecker, P. L. Management of lower-extremity deformities in osteogenesis imperfecta with extensible intramedullary rod technique: a 20-year experience. J. Pediatr. Orthop. 18, 88-94 (1998). (Pubitemid 28051576)
168. Zionts, L. E., Ebramzadeh, E. & Stott, N. S. Complications in the use of the Bailey-Dubow extensible nail. Clin. Orthop. Relat. Res. 186-195 (1998). (Pubitemid 28160823)
169. El-Adl, G., Khalil, M. A., Enan, A., Mostafa, M. F. & El-Lakkany, M. R. Telescoping versus non-telescoping rods in the treatment of osteogenesis imperfecta. Acta Orthop. Belg. 75, 200-208 (2009).
170. Esposito, P. & Plotkin, H. Surgical treatment of osteogenesis imperfecta: current concepts. Curr. Opin. Pediatr. 20, 52-57 (2008).
171. Boutaud, B. & Laville, J. M. Elastic sliding central medullary nailing with osteogenesis imperfecta. Fourteen cases at eight years follow-up [French]. Rev. Chir. Orthop. Reparatrice Appar. Mot. 90, 304-311 (2004).
172. Munns, C. F., Rauch, F., Zeitlin, L., Fassier, F. & Glorieux, F. H. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J. Bone Miner. Res. 19, 1779-1786 (2004). (Pubitemid 41103428)
173. Hanscom, D. A. & Bloom, B. A. The spine in osteogenesis imperfecta. Orthop. Clin. North Am. 19, 449-458 (1988).
174. Topouchian, V., Finidori, G., Glorion, C., Padovani, J. P. & Pouliquen, J. C. Posterior spinal fusion for kypho-scoliosis associated with osteogenesis imperfecta: long-term results [French]. Rev. Chir. Orthop. Reparatrice Appar. Mot. 90, 525-532 (2004). (Pubitemid 39422891)
175. Janus, G. J., Finidori, G., Engelbert, R. H., Pouliquen, M. & Pruijs, J. E. Operative treatment of severe scoliosis in osteogenesis imperfecta: results of 20 patients after halo traction and posterior spondylodesis with instrumentation. Eur. Spine J. 9, 486-491 (2000). (Pubitemid 32005651)
176. Rauch, F. & Glorieux, F. H. Treatment of children with osteogenesis imperfecta. Curr. Osteoporos. Rep. 4, 159-164 (2006). (Pubitemid 46030453)
177. Cheung, M. S. & Glorieux, F. H. Osteogenesis imperfecta: update on presentation and management. Rev. Endocr. Metab. Disord. 9, 153-160 (2008).
178. Bachrach, L. K. & Ward, L. M. Clinical review 1: Bisphosphonate use in childhood osteoporosis. J. Clin. Endocrinol. Metab. 94, 400-409 (2009).
179. Phillipi, C. A., Remmington, T. & Steiner, R. D. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD005088. doi:10.1002/14651858.CD005088.pub2 (2008).
180. Rauch, F., Travers, R., Plotkin, H. & Glorieux, F. H. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J. Clin. Invest. 110, 1293-1299 (2002). (Pubitemid 35285755)
181. Marini, J. C. Should children with osteogenesis imperfecta be treated with bisphosphonates? Nat. Clin. Pract. Endocrinol. Metab. 2, 14-15 (2006).
182. Land, C., Rauch, F., Munns, C. F., Sahebjam, S. & Glorieux, F. H. Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment. Bone 39, 901-906 (2006). (Pubitemid 44311714)
183. Castillo, H. & Samson-Fang, L. Effects of bisphosphonates in children with osteogenesis imperfecta: an AACPDM systematic review. Dev. Med. Child. Neurol. 51, 17-29 (2009).
184. Ward, L. M. et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J. Clin. Endocrinol. Metab. 96, 355-364 (2011).
185. Marini, J. C. Bone: Use of bisphosphonates in children-proceed with caution. Nat. Rev. Endocrinol. 5, 241-243 (2009).
186. Uveges, T. E. et al. Alendronate treatment of the brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation. J. Bone Miner. Res. 24, 849-859 (2009).
187. Malmgren, B., Aström, E. & Söderhäll, S. No osteonecrosis in jaws of young patients with osteogenesis imperfecta treated with bisphosphonates. J. Oral Pathol. Med. 37, 196-200 (2008). (Pubitemid 351347604)
188. Ward, K. A., Adams, J. E., Freemont, T. J. & Mughal, M. Z. Can. bisphosphonate treatment be stopped in a growing child with skeletal fragility? Osteoporos. Int. 18, 1137-1140 (2007). (Pubitemid 47019997)
189. Hussar, D. A. & Stevenson, T. New drugs: Denosumab, dienogest/estradiol valerate, and polidocanol. J. Am. Pharm. Assoc. 50, 658-662 (2003).
190. Bargman, R., Huang, A., Boskey, A. L., Raggio, C. & Pleshko, N. RANKL inhibition improves bone properties in a mouse model of osteogenesis imperfecta. Connect. Tissue Res. 51, 123-131 (2010).
191. Dunn, M. D., Park, C. H., Kostenuik, P. J., Kapila, S. & Giannobile, W. V. Local delivery of osteoprotegerin inhibits mechanically mediated bone modeling in orthodontic tooth movement. Bone 41, 446-455 (2007). (Pubitemid 47199141)
192. Kamoun-Goldrat, A., Ginisty, D. & Le Merrer, M. Effects of bisphosphonates on tooth eruption in children with osteogenesis imperfecta. Eur. J. Oral Sci. 116, 195-198 (2008).
193. Paszty, C., Turner, C. H. & Robinson, M. K. Sclerostin: a gem from the genome leads to bone-building antibodies. J. Bone Miner. Res. 25, 1897-1904 (2010).
194. Antoniazzi, F. et al. Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis. J. Pediatr. 129, 432-439 (1996). (Pubitemid 27484151)
195. Antoniazzi, F. et al. GH in combination with bisphosphonate treatment in osteogenesis imperfecta. Eur. J. Endocrinol. 163, 479-487 (2010).
196. Cabral, W. A. & Marini, J. C. High proportion of mutant osteoblasts is compatible with normal skeletal function in mosaic carriers of osteogenesis imperfecta. Am. J. Hum. Genet. 74, 752-760 (2004). (Pubitemid 38420105)
197. Li, F., Wang, X. & Niyibizi, C. Distribution of single-cell expanded marrow derived progenitors in a developing mouse model of osteogenesis imperfecta following systemic transplantation. Stem Cells 25, 3183-3193 (2007). (Pubitemid 350294444)
198. Guillot, P. V. et al. Intrauterine transplantation of human fetal mesenchymal stem cells from first-trimester blood repairs bone and reduces fractures in osteogenesis imperfecta mice. Blood 111, 1717-1725 (2008). (Pubitemid 351213464)
199. Chamberlain, J. R. et al. Gene targeting in stem cells from individuals with osteogenesis imperfecta. Science 303, 1198-1201 (2004). (Pubitemid 38233586)
200. Chamberlain, J. R. et al. Gene targeting of mutant COL1A2 alleles in mesenchymal stem cells from individuals with osteogenesis imperfecta. Mol. Ther. 16, 187-193 (2008).
201. Millington-Ward, S., McMahon, H. P. & Farrar, G. J. Emerging therapeutic approaches for osteogenesis imperfecta. Trends Mol. Med. 11, 299-305 (2005). (Pubitemid 40804794)
202. Dawson, P. A. & Marini, J. C. Hammerhead ribozymes selectively suppress mutant type I collagen mRNA in osteogenesis imperfecta fibroblasts. Nucleic Acids Res. 28, 4013-4020 (2000).
203. Navon, A. & Ciechanover, A. The 26 S. proteasome: from basic mechanisms to drug targeting. J. Biol. Chem. 284, 33713-33718 (2009).
204. Sloan, L. A., Fillmore, M. C. & Churcher, I. Small-molecule modulation of cellular chaperones to treat protein misfolding disorders. Curr. Opin. Drug Discov. Devel. 12, 666-681 (2009).
205. Rochet, J. C. Novel therapeutic strategies for the treatment of protein-misfolding diseases. Expert Rev. Mol. Med. 9, 1-34 (2007).
206. Bonadio, J. et al. A murine skeletal adaptation that significantly increases cortical bone mechanical properties. Implications for human skeletal fragility. J. Clin. Invest. 92, 1697-1705 (1993). (Pubitemid 23304532)
207. Stacey, A. et al. Perinatal lethal osteogenesis imperfecta in transgenic mice bearing an engineered mutant pro-alpha 1(I) collagen gene. Nature 332, 131-136 (1988). (Pubitemid 18083558)
208. Khillan, J. S., Olsen, A. S., Kontusaari, S., Sokolov, B. & Prockop, D. J. Transgenic mice that express a mini-gene version of the human gene for type I procollagen (COL1A1) develop a phenotype resembling a lethal form of osteogenesis imperfecta. J. Biol. Chem. 266, 23373-23379 (1991). (Pubitemid 21908803)
209. Forlino, A., Porter, F. D., Lee, E. J., Westphal, H. & Marini, J. C. Use of the Cre/lox recombination system to develop a non-lethal knock-in murine model for osteogenesis imperfecta with an alpha1(I) G349C substitution. Variability in phenotype in BrtlIV mice. J. Biol. Chem. 274, 37923-37931 (1999). (Pubitemid 30026860)
210. Harbers, K., Kuehn, M., Delius, H. & Jaenisch, R. Insertion of retrovirus into the first intron of alpha 1(I) collagen gene to embryonic lethal mutation in mice. Proc. Natl Acad. Sci. USA 81, 1504-1508 (1984). (Pubitemid 14174531)
211. Chipman, S. D. et al. Defective pro alpha 2(I) collagen synthesis in a recessive mutation in mice: a model of human osteogenesis imperfecta. Proc. Natl Acad. Sci. USA 90, 1701-1705 (1993). (Pubitemid 23069924)
212. Baek, W. Y. et al. Positive regulation of adult bone formation by osteoblast-specific transcription factor osterix. J. Bone Miner. Res. 24, 1055-1065 (2009).
213. Khoshnoodi, J., Cartailler, J. P., Alvares, K., Veis, A. & Hudson, B. G. Molecular recognition in the assembly of collagens: terminal noncollagenous domains are key recognition modules in the formation of triple helical protomers. J. Biol. Chem. 281, 38117-38121 (2006). (Pubitemid 46041935)
214. Nishikawa, Y. et al. A structure-activity relationship study elucidating the mechanism of sequence-specific collagen recognition by the chaperone HSP47. Bioorg. Med. Chem. 18, 3767-3775 (2010).
215. Chessler, S. D. & Byers, P. H. BiP binds type I procollagen pro alpha chains with mutations in the carboxyl-terminal propeptide synthesized by cells from patients with osteogenesis imperfecta. J. Biol. Chem. 268, 18226-18233 (1993). (Pubitemid 23260347)